ClinicalTrials.gg
RecruitingNCT07665437Updated Nov 9, 2026

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

A Phase 3 interventional study of Remibrutinib in Hidradenitis Suppurativa, sponsored by Novartis Pharmaceuticals. Recruiting at 61 sites in 12 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 9, 2026First sites in 8 new countriesPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
710
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies in Hidradenitis Suppurativa by Novartis — 9 open to participants now, 14 under way, 3 of them phase 3. Hidradenitis Suppurativa · Novartis.

Planned enrollment
Largest of 10
710 · median 545
Started
2026
with 4 others
Phase 3
6 of 21
1 open now
Primary completion
2031-10
later than 13 of 13 live
Registered
19th of 21
by date

Among the 21 studies in Hidradenitis Suppurativa by Novartis, this one has the largest planned enrollment of the 10 interventional ones that give a count, is one of 5 that started in 2026, is one of 6 in phase 3, reaches primary completion later than 13 of the 13 other live ones, and was the 19th registered.

Hidradenitis Suppurativa

285 studies on the registry are indexed under Hidradenitis Suppurativa; 88 are open to participants now.

Browse Hidradenitis Suppurativa studies →

Open to participants now

9 of the 21 studies in Hidradenitis Suppurativa by Novartis are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Who these studies take

Of the 61 Hidradenitis Suppurativa studies recruiting now, 33 (54%) set no upper age limit and 17 (28%) stop at 75 or younger; 13 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Hidradenitis Suppurativa by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety, tolerability and efficacy of remibrutinib (LOU064) in adult participants with moderate to severe hidradenitis suppurativa (HS) who have completed either of the preceding Phase 3 studies, CLOU064J12301 or CLOU064J12302.

Read the detailed description

This is a global Phase 3, multicentre, double-blind, double-dummy, parallel-group extension study. It fulfils the Novartis commitment to provide post-trial access.

The study includes a double-blind and an open-label treatment phase:

Double-blind, double-dummy treatment continues from Week 68 (end of core study) until final database lock (DBL) of both core studies or until up titration. Participants remain on the same blinded regimen they were on during Treatment Period 2 of the preceding Phase 3 studies.

After final DBL of both core studies, treatment transitions to open-label.

Participants will continue treatment until commercial availability and reimbursement in their country, another access mechanism is available, or 4 years of extension treatment is completed.

Participants who discontinue treatment early or do not transition to commercial remibrutinib will enter a 4-week treatment-free safety follow-up.

03

Conditions studied

  • Hidradenitis Suppurativa

Keywords

  • BTK inhibitor
  • hidradenitis suppurativa
  • HiSCR
  • remibrutinib
  • Phase 3
  • extension study
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Signed must be obtained before any assessment is performed.
  • Participant has completed the full study treatment period according to the protocol (68 weeks) in the core studies (CLOU064J12301 or CLOU064J12302).
  • Participant does not meet any treatment discontinuation criteria of the core study at Week 68.

Key Exclusion Criteria:

  • Ongoing or planned use of prohibited HS or non-HS treatments.
  • Participants not expected to benefit from participation in the extension study or participants expected to be exposed to an undue safety risk if participating in the extension study, as assessed by the Investigator.
  • Current severe progressive or uncontrolled disease, which in the judgment of the Investigator renders the participant unsuitable for the study.

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
710 participants (estimated)

Study arms

  • Experimental
    Remibrutinib Dose A

    Participants randomized during the core study to receive remibrutinib Dose A

    Drug: Remibrutinib

  • Experimental
    Remibrutinib Dose B

    Participants randomized during the core study to receive remibrutinib Dose B

    Drug: Remibrutinib

Interventions

  • Remibrutinib Dose A and B (oral)

    Also known as: LOU064

06

What researchers measure

Primary outcomes

  1. Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Evaluate the safety of long-term treatment with remibrutinib in adult participants with moderate to severe Hidradenitis Suppurativa.

    Time frame: Baseline, up to Week 280

Secondary outcomes

  1. Proportion of participants with AN50/75/90 response

    Achievement of AN50/75/90 is defined as at least a 50/75/90 (respectively)% decrease in Abscess and Inflammatory Nodule (AN) count compared to baseline.

    Time frame: Baseline, up to Week 276

  2. Mean Percentage change from baseline in International Hidradenitis Suppurativa severity score system (IHS4)

    The IHS4 is a disease severity score calculated as a weighted sum of inflammatory lesion counts: nodules (×1), abscesses (×2), and draining tunnels (×4). Scores are categorised as mild (≤3), moderate (4-10), and severe (≥11). Higher scores indicate greater disease severity (worse outcome).

    Time frame: Baseline, up to Week 276

  3. Proportion of participants with Hidradenitis suppurativa clinical response (HiSCR)50/75/90 response

    Achievement of HiSCR50/75/90 is defined as at least a 50/75/90 (respectively)% decrease in AN count with no increase in the number of abscesses and in the number of draining tunnels/fistulae compared to baseline.

    Time frame: Baseline, up to Week 276

  4. Proportion of participants with clinical response in HS-related skin pain (numerical rating scale [NRS] 30), at worst

    Achievement of NRS30 among participants with baseline NRS ≥ 3 (in the core studies CLOU064J12301 and CLOU064J12302). NRS30 is defined as at least a 30% reduction and at least 2-unit reduction from baseline in Patient's Global Assessment of Skin Pain - at worst over the past 7 days.

    Time frame: Baseline, up to Week 276

07

Study locations

61 of 61 sites recruiting
  • Total Skin and Beauty Dermatology Center PC
    Birmingham, Alabama 35205, United States
    Recruiting
  • Johnson Dermatology
    Fort Smith, Arkansas 72916, United States
    Recruiting
  • Arkansas Research Trials
    North Little Rock, Arkansas 72117, United States
    Recruiting
  • Ctr for Dermatology Clinical Res
    Fremont, California 95438, United States
    Recruiting
  • USC Keck School of Medicine
    Los Angeles, California 90033, United States
    Recruiting
  • Olive View UCLA Medical Center
    Sylmar, California 91342, United States
    Recruiting
  • Clinical Trials Research Institute
    Thousand Oaks, California 91320, United States
    Recruiting
  • University of MiamiHealth System
    Miami, Florida 33125, United States
    Recruiting
  • Floridian Research Institute
    Miami, Florida 33179, United States
    Recruiting
  • University Of South Florida
    Tampa, Florida 33612, United States
    Recruiting
    • Zachary Leniek · Contactleniekz@usf.edu · +1 813 974 6378
    • Ann Lin · Principal investigator
  • Endeavor Health
    Glenview, Illinois 60077, United States
    Recruiting
  • Dundee Dermatology
    West Dundee, Illinois 60118, United States
    Recruiting
  • Southern IN Clinical Trials
    New Albany, Indiana 47150, United States
    Recruiting
  • Revival Research Institute
    Troy, Michigan 48084, United States
    Recruiting
  • Skin Specialists PC
    Omaha, Nebraska 68144, United States
    Recruiting
    • Kayleigh Koziol · Contactkayleigh@lovelyskin.com · +1 402 334 7546
    • Joel Schlessinger · Principal investigator
  • Cameron Dermatology
    New York, New York 10023, United States
    Recruiting
  • Icahn School Of Med At Mount Sinai
    New York, New York 10029, United States
    Recruiting
  • Skinsearch of Rochester Inc
    Rochester, New York 14623, United States
    Recruiting
  • OnSite Clinical Solutions LLC
    Huntersville, North Carolina 28078, United States
    Recruiting
    • April Page · Contactapage@onsiteclinical.com · +1 800 785 3150
    • Nicole Seminara-Zambrzycka · Principal investigator
  • Optima Research Boardman
    Boardman, Ohio 44512, United States
    Recruiting
  • Apex Clinical Research Center LLC
    Mayfield Heights, Ohio 44124, United States
    Recruiting
  • UP Medical Center H System
    Pittsburgh, Pennsylvania 15213-3403, United States
    Recruiting
    • Carisa Byich · Contactbyichcj@upmc.edu · +1 412 647 2013
    • Joe Kuanheng Tung · Principal investigator
  • Clinical Research Ctr of Carolinas
    Charleston, South Carolina 29407, United States
    Recruiting
  • Medical University of South Carolina MUSC
    Charleston, South Carolina 29425, United States
    Recruiting
    • Madeline Richmond · Contactrichmoma@musc.edu · +1 843 792 9784
    • Lara Wine Lee · Principal investigator
  • RFSA Dermatology
    San Antonio, Texas 78213, United States
    Recruiting
  • Center for Clinical Studies-Lee
    Webster, Texas 77598, United States
    Recruiting
    • Karina Gonzalez · Contactkgonzalez@ccstexas.com · +1 281 333 2288
    • Patricia C Lee · Principal investigator
  • Forefront Dermatology
    Vienna, Virginia 22182, United States
    Recruiting
  • Novartis Investigative Site
    Caba, Buenos Aires C1119ACN, Argentina
    Recruiting
  • Novartis Investigative Site
    CABA, Buenos Aires C1425BEA, Argentina
    Recruiting
  • Novartis Investigative Site
    Rosario, Santa Fe Province S2000DBS, Argentina
    Recruiting
  • Novartis Investigative Site
    CABA, C1012AAY, Argentina
    Recruiting
  • Novartis Investigative Site
    CABA, C1428DZF, Argentina
    Recruiting
  • Novartis Investigative Site
    Sydney, New South Wales 2010, Australia
    Recruiting
  • Novartis Investigative Site
    Melbourne, Victoria 3004, Australia
    Recruiting
  • Novartis Investigative Site
    Parkville, Victoria 3050, Australia
    Recruiting
  • Novartis Investigative Site
    Edmonton, Alberta T6G 1C3, Canada
    Recruiting
  • Novartis Investigative Site
    London, Ontario N6H 5L5, Canada
    Recruiting
  • Novartis Investigative Site
    Montreal, Quebec H1Y 3L1, Canada
    Recruiting
  • Novartis Investigative Site
    Québec, Quebec G1V 4T3, Canada
    Recruiting
  • Novartis Investigative Site
    Beijing, 100144, China
    Recruiting
  • Novartis Investigative Site
    Prague, 180 81, Czechia
    Recruiting
  • Novartis Investigative Site
    Lyon, 69003, France
    Recruiting
  • Novartis Investigative Site
    Reims, 51100, France
    Recruiting
  • Novartis Investigative Site
    Rouen, 76031, France
    Recruiting
  • Novartis Investigative Site
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
    Recruiting
  • Novartis Investigative Site
    Würzburg, Bavaria 97080, Germany
    Recruiting
  • Novartis Investigative Site
    Darmstadt, Hesse 64283, Germany
    Recruiting
  • Novartis Investigative Site
    Düsseldorf, North Rhine-Westphalia 40225, Germany
    Recruiting
  • Novartis Investigative Site
    Bochum, 44791, Germany
    Recruiting
  • Novartis Investigative Site
    Minden, 32429, Germany
    Recruiting
  • Novartis Investigative Site
    Ancona, AN 60020, Italy
    Recruiting
  • Novartis Investigative Site
    Muar town, Johor 84000, Malaysia
    Recruiting
  • Novartis Investigative Site
    Kuala Lumpur, Kuala Lumpur 50586, Malaysia
    Recruiting
  • Novartis Investigative Site
    Ipoh, Perak 30450, Malaysia
    Recruiting
  • Novartis Investigative Site
    George Town, Pulau Pinang 10450, Malaysia
    Recruiting
  • Novartis Investigative Site
    Kota Kinabalu, Sabah 88586, Malaysia
    Recruiting
  • Novartis Investigative Site
    Selangor Darul Ehsan, 68100, Malaysia
    Recruiting
  • Novartis Investigative Site
    Warsaw, Masovian Voivodeship 02-953, Poland
    Recruiting
  • Novartis Investigative Site
    Barcelona, Catalonia 08003, Spain
    Recruiting
  • Novartis Investigative Site
    Las Palmas GC, 35010, Spain
    Recruiting
  • Novartis Investigative Site
    Madrid, 28041, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Oct 2031, 63 months after the start.

Of 26 phase 3 interventional studies under Hidradenitis Suppurativa, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 38. This study's planned 63 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2026
First posted
Jun 24, 2026
StartActual
Jul 10, 2026
Primary completionEst.
Oct 15, 2031
CompletionEst.
Oct 15, 2031
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
41 sites added — first sites in China, Malaysia, Spain, France, Germany and 3 more
All 8 countries

China, Malaysia, Spain, France, Germany, Czechia, Italy, Poland

Show 41 added (14 United States, 6 Malaysia, 6 Germany, 3 Canada, 3 Spain, 3 France, 1 Argentina, 1 China, 1 Australia, 1 Czechia, 1 Italy, 1 Poland)
  • Floridian Research Institute · Miami, United States
  • University Of South Florida · Tampa, United States
  • Icahn School Of Med At Mount Sinai · New York, United States
  • OnSite Clinical Solutions LLC · Huntersville, United States
  • Center for Clinical Studies-Lee · Webster, United States
  • Novartis Investigative Site · CABA, Argentina
  • Novartis Investigative Site · Edmonton, Canada
  • Novartis Investigative Site · Montreal, Canada
  • Novartis Investigative Site · Québec, Canada
  • Novartis Investigative Site · Beijing, China
  • Novartis Investigative Site · Ipoh, Malaysia
  • Novartis Investigative Site · Kota Kinabalu, Malaysia
  • Novartis Investigative Site · Selangor Darul Ehsan, Malaysia
  • Novartis Investigative Site · Barcelona, Spain
  • Total Skin and Beauty Dermatology Center PC · Birmingham, United States
  • Arkansas Research Trials · North Little Rock, United States
  • UP Medical Center H System · Pittsburgh, United States
  • Novartis Investigative Site · Parkville, Australia
  • Novartis Investigative Site · Lyon, France
  • Novartis Investigative Site · Bochum, Germany
  • Novartis Investigative Site · Muar town, Malaysia
  • Novartis Investigative Site · George Town, Malaysia
  • Novartis Investigative Site · Las Palmas GC, Spain
  • Novartis Investigative Site · Madrid, Spain
  • University of MiamiHealth System · Miami, United States
  • Revival Research Institute · Troy, United States
  • Skinsearch of Rochester Inc · Rochester, United States
  • Medical University of South Carolina MUSC · Charleston, United States
  • RFSA Dermatology · San Antonio, United States
  • Forefront Dermatology · Vienna, United States
  • …and 11 more on the registry record
across 3 updates, Sep 28, 2026 – Nov 9, 2026
Primary completion
Oct 24, 2031→Oct 15, 2031
moved 2 times, Oct 13, 2026 – Nov 9, 2026
Study completion
Oct 24, 2031→Oct 15, 2031
moved 2 times, Oct 13, 2026 – Nov 9, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Clinical Trials Research Institute · Thousand Oaks, United StatesContact none listed→•••7482
  • UP Medical Center H System · Pittsburgh, United StatesContact f•••@upmc.edu · •••2013→b•••@upmc.edu · •••2013
across 2 updates, Sep 28, 2026 – Nov 9, 2026
Show all 3 updates
  1. Nov 9, 2026
    17 sites added — first sites in Czechia, Italy and Poland
    Show 17 added (6 United States, 5 Germany, 2 France, 1 Czechia, 1 Italy, 1 Malaysia, 1 Poland)
    • University of MiamiHealth System · Miami, United States
    • Revival Research Institute · Troy, United States
    • Skinsearch of Rochester Inc · Rochester, United States
    • Medical University of South Carolina MUSC · Charleston, United States
    • RFSA Dermatology · San Antonio, United States
    • Forefront Dermatology · Vienna, United States
    • Novartis Investigative Site · Prague, Czechia
    • Novartis Investigative Site · Reims, France
    • Novartis Investigative Site · Rouen, France
    • Novartis Investigative Site · Freiburg im Breisgau, Germany
    • Novartis Investigative Site · Würzburg, Germany
    • Novartis Investigative Site · Darmstadt, Germany
    • Novartis Investigative Site · Düsseldorf, Germany
    • Novartis Investigative Site · Minden, Germany
    • Novartis Investigative Site · Ancona, Italy
    • Novartis Investigative Site · Kuala Lumpur, Malaysia
    • Novartis Investigative Site · Warsaw, Poland
    Primary completion Oct 29, 2031→Oct 15, 2031
    Study completion Oct 29, 2031→Oct 15, 2031
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Clinical Trials Research Institute · Thousand Oaks, United StatesContact none listed→•••7482
    • UP Medical Center H System · Pittsburgh, United StatesContact f•••@upmc.edu · •••2013→b•••@upmc.edu · •••2013
    + 1 other change: verification date
  2. Oct 13, 2026
    10 sites added — first sites in France and Germany
    Show 10 added (3 United States, 2 Malaysia, 2 Spain, 1 Australia, 1 France, 1 Germany)
    • Total Skin and Beauty Dermatology Center PC · Birmingham, United States
    • Arkansas Research Trials · North Little Rock, United States
    • UP Medical Center H System · Pittsburgh, United States
    • Novartis Investigative Site · Parkville, Australia
    • Novartis Investigative Site · Lyon, France
    • Novartis Investigative Site · Bochum, Germany
    • Novartis Investigative Site · Muar town, Malaysia
    • Novartis Investigative Site · George Town, Malaysia
    • Novartis Investigative Site · Las Palmas GC, Spain
    • Novartis Investigative Site · Madrid, Spain
    Primary completion Oct 24, 2031→Oct 29, 2031
    Study completion Oct 24, 2031→Oct 29, 2031
    + 1 other change: verification date
  3. Sep 28, 2026
    14 sites added — first sites in China, Malaysia and Spain
    Show 14 added (5 United States, 3 Canada, 3 Malaysia, 1 Argentina, 1 China, 1 Spain)
    • Floridian Research Institute · Miami, United States
    • University Of South Florida · Tampa, United States
    • Icahn School Of Med At Mount Sinai · New York, United States
    • OnSite Clinical Solutions LLC · Huntersville, United States
    • Center for Clinical Studies-Lee · Webster, United States
    • Novartis Investigative Site · CABA, Argentina
    • Novartis Investigative Site · Edmonton, Canada
    • Novartis Investigative Site · Montreal, Canada
    • Novartis Investigative Site · Québec, Canada
    • Novartis Investigative Site · Beijing, China
    • Novartis Investigative Site · Ipoh, Malaysia
    • Novartis Investigative Site · Kota Kinabalu, Malaysia
    • Novartis Investigative Site · Selangor Darul Ehsan, Malaysia
    • Novartis Investigative Site · Barcelona, Spain
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Clinical Trials Research Institute · Thousand Oaks, United StatesContact l•••@northridgetrials.com→j•••@eliteclinicalnetwork.com

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07665437
Responsible party
Sponsor
First posted
Jun 24, 2026
Start date
Jul 10, 2026
Primary completion
Oct 15, 2031 (estimated)
Completion
Oct 15, 2031 (estimated)
Last update
Nov 9, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
1-888-669-6682
Novartis Pharmaceuticals
Contact
+41613241111

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Remibrutinib

Start the discussion